Hedge fund BVF invested $52 million in Disc Medicine (IRON) by acquiring 650,000 shares in Q4, demonstrating conviction in the clinical-stage biotech company despite recent FDA setbacks. The investment was made before the FDA's Complete Response Letter in February and a subsequent 20% stock decline. With $791 million in cash runway through 2029, Disc Medicine's investment thesis now hinges on Phase 3 APOLLO trial data expected in Q4 and a potential FDA decision by mid-2027.

The FDA has delayed reviews of several drugs in the Trump administration's fast-track approval program (CNPV) due to safety and efficacy concerns. Disc Medicine's bitopertin for rare blood disorder, Sanofi's Tzield for type 1 diabetes, and Eli Lilly's orforglipron weight-loss pill have all experienced timeline extensions. Regulators cited issues including questionable trial endpoints, adverse events including seizures and deaths, and abuse potential concerns. The delays suggest the one- to two-month review targets may be too aggressive for thorough evaluation.

Disc Medicine reported promising results from its Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis patients, demonstrating substantial hematologic responses across different patient subgroups and transfusion statuses.

Bain Capital Life Sciences Investors completely sold its entire stake in Disc Medicine during Q3 2025, disposing of 583,500 shares worth approximately $30.90 million, signaling a potential shift in institutional sentiment towards the biotech company.

Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.

Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential commercialization of bitopertin and fund research and development.

Disc Medicine received an FDA Commissioner's National Priority Voucher for bitopertin, an investigational drug targeting erythropoietic protoporphyria (EPP), with potential for accelerated approval for patients aged 12 and older.

Disc Medicine reported a Q2 2025 net loss of $55.2 million, with increased research and development expenses. The company is advancing clinical trials for bitopertin and other pipeline programs targeting blood disorders, with a strong cash position of $650 million to fund operations through 2028.

Disc Medicine, a clinical-stage biopharmaceutical company, announced the pricing of its upsized public offering of common stock and pre-funded warrants, raising approximately $225.5 million. The company plans to use the proceeds to fund research, clinical development, and potential commercialization of its product candidates.

Disc Medicine, a clinical-stage biopharmaceutical company, announced the grant of an inducement equity award to a new employee, including a stock option and a restricted stock unit award.

Disc Medicine presented positive updates across its portfolio, including updates from ongoing clinical studies and new preclinical data supporting the use of its investigational agents in existing and additional indications.

Disc Medicine announced positive feedback from its end-of-Phase 2 meeting with the FDA, supporting the regulatory path forward for bitopertin in EPP. The company plans to initiate the APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+, by mid-2025. The FDA agreed on the study design, including the potential for accelerated approval based on reduction of PPIX as a surrogate endpoint.